Cancers, Free Full-Text

After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.

Cancers, Free Full-Text

Celltracker Zip Get File - Colaboratory

Particle Illusion 3.02 Download - Colaboratory

Journal of Cancer Research and Clinical Oncology

CA: A Cancer Journal for Clinicians - Wiley Online Library

Cancers, Free Full-Text

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Bray - 2018 - CA: A Cancer Journal for Clinicians - Wiley Online Library

Mr Bhujade Parallel Computing Pdf Download - Colaboratory

Cancers, Free Full-Text

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

2Go Bb Symbols By Slow Poison - Colaboratory